StockWatch
·
GODAVARI BIOREFINERIES · Q2 FY27 · THE VERDICT

Chemicals Beat Can't Escape Consolidated Loss

Bio-chemicals beat guidance and margins expanded, but consolidated net loss of ₹15.2 Cr persists despite 27.5% revenue growth. Sugar and ethanol losses of ₹19.3 Cr EBITDA are consuming profits — the real question is whether debottlenecking can overcome it.

Q2 FY27 resultsGODAVARIBGodavari Biorefineries Ltd13 Nov 2026 · 6 min read
Bio-chemicals revenue

₹204.2 Cr

Beat ₹190 Cr guidance · +38.8% YoY

Bio-chemicals EBITDA margin

10.8%

+60 bps YoY · Up from 10.2%

Consolidated net loss

-₹15.2 Cr

Narrowed 63% from -₹41.6 Cr YoY · Still loss

Sugar/ethanol EBITDA loss

-₹19.3 Cr

Q2 segment drag · Better than -₹23.1 Cr YoY

The split tells the story. Godavari's bio-chemicals business beat guidance by ₹14.2 Cr and expanded margins by 60 basis points — exactly the debottlenecking story management has been selling. But the consolidated result is a loss of ₹15.2 Cr, despite revenue growth of 27.5%. The reason: the sugar and ethanol segment lost ₹19.3 Cr in EBITDA in Q2 alone. Chemicals are roaring; the rest of the business is not just quiet, it's bleeding.

Where the profit went

Q2 FY27 segment contributions, ₹ Cr
-24.27-7.169.9627.0722.1Bio-chemicals EBITDA-19.3Sugar/ethanol loss2.8Net EBITDA
Bio-chemicals EBITDA of ₹22.1 Cr is nearly consumed by sugar/ethanol losses. Consolidated NPM is -2.8% despite 27.5% revenue growth.

The sugar and ethanol business is seasonal — management says Q3 and Q4 are typically profitable — but the scale of Q2 loss (₹19.3 Cr EBITDA) is material and ongoing. Sugar revenue fell slightly due to monsoon failure in Maharashtra and Karnataka and government restrictions on diverting sugarcane juice to ethanol. Ethanol, despite a new grain-based distillery commissioned in Q1 (800 kL/day total capacity), faced feedstock constraints and weak pricing. Management expects H2 recovery, but no quantified guidance was offered.

Management claims vs. what holds up

Validating key assertions from the call

Bio-chemicals revenue ₹204.2 Cr beat ₹190 Cr guidance

Delivered ₹204.2 Cr vs ₹190 Cr; +7.5% beat, +38.8% YoY growth vs ₹147 Cr Q2 FY26

Supported

Bio-chemicals EBITDA margin improved to 10.8%

₹22.1 Cr EBITDA ÷ ₹204.2 Cr revenue = 10.83%; up 60 bps YoY

Supported

Consolidated net loss narrowed to ₹15.2 Cr from ₹41.6 Cr YoY

Q2 FY26 loss -₹41.6 Cr, Q2 FY27 loss -₹15.2 Cr; 63.4% improvement. Still loss, not profit.

Supported (with context)

₹240 Cr quarterly chemicals target by FY28 is achievable

Currently ₹204.2 Cr; requires 17.6% CAGR over ~5 quarters. Dependent on ₹25 Cr capex not yet proven.

Overstated—projection only

Consolidated operations moving toward profitability

Consolidated NPM -2.8% in Q2 FY27. Sugar loss ₹19.3 Cr EBITDA. No PAT timeline disclosed.

Contradicted

What changed on this call

  • Bio-chemicals beat Q2 guidance by ₹14.2 Cr (₹204.2 vs ₹190 Cr); driven by debottlenecking progress and higher Hormuz-related pricing.

  • Consolidated loss narrowed 63% YoY but remains -₹15.2 Cr; no path to profitability timeline quantified.

  • ₹240 Cr/qtr chemicals target by FY28 reaffirmed, not raised; same ₹25 Cr capex plan from Q1 guidance.

  • Grain-based distillery (200 kL/day) now operational; ethanol EBITDA improved to ₹10.6 Cr from ₹4.7 Cr YoY despite feedstock headwinds.

  • Sugar/ethanol segment loss persists (₹19.3 Cr EBITDA loss Q2) due to monsoon failure and government policy tightening on ethanol diversion.

The bull-bear ledger

  • Bio-chemicals beat Q2 guidance by ₹14.2 Cr; margins expanded 60 bps; debottlenecking strategy working as expected.

  • Strong chemicals growth (38.8% YoY) validates market demand for bio-based specialty chemicals; patent portfolio differentiates.

  • Multi-feedstock distillery (grain + cane) reduces single-feedstock risk; ethanol EBITDA doubled YoY to ₹10.6 Cr.

  • Near-term catalysts: DME pilot results March 2027, TNBC trials Q3 FY27, 20-25 new specialty chemicals launching April-Sept 2027.

  • Consolidated loss persists at -₹15.2 Cr despite 27.5% revenue growth; sugar/ethanol loss (₹19.3 Cr EBITDA) is material and ongoing.

  • No quantified consolidated profitability timeline; management deferred to H2 seasonality and vague ₹240 Cr target without credible path to PAT positive.

  • Feedstock and government policy volatility (monsoon, sugarcane diversion, grain prices) create headwinds management cannot fully control.

  • ₹240 Cr/qtr target by FY28 is unproven; requires debottlenecking capex to deliver proportional revenue and margin gains.

How the street is positioned

The stock stands at ₹218.06, down 46.63% from its all-time high of ₹408.6 and trading below both the 50-day (₹227.96) and 200-day (₹269.24) moving averages. The trend is bearish; RSI sits at 46.7 (neutral), and volume is decreasing. This is not a stock finding support near its lows — it is a stock that has been rerated lower and lower as consolidated losses accumulated.

Ownership flows confirm the challenge. FII holdings collapsed from 0.98% in FY26 Q4 to 0.22% in FY27 Q1, a drop of 76 basis points in a single quarter. Domestic institutions remain steady at ~10%, and promoters hold firm at 63.31%, but the FII exit is a clear signal: foreign money is not waiting for the consolidated loss story to resolve. Bulk deals over the past six months show research and trading desks accumulating near ₹252 — a tactical trade, not a strategic vote of confidence.

The post-result market reaction appears muted (volume trending lower), suggesting the street views this as neither a relief bounce nor a capitulation flush. The chemicals beat is noted; the consolidated loss is priced in. The real re-rating will come only if management articulates a path to consolidated profitability, or if it delivers on ₹240 Cr chemicals run-rate in real time.

Ranked risks for a holder

Concerns ranked by impact on shareholder value

Consolidated PAT negative despite 27.5% revenue growth

High

Losses are structural, not cyclical one-offs. No credible timeline to breakeven disclosed. Every quarter of loss erodes shareholder value and constrains capex flexibility.

Sugar/ethanol segment loss-making; feedstock and policy volatility uncontrollable

High

₹19.3 Cr EBITDA loss Q2 driven by monsoon, government ethanol restrictions, grain price inflation. H2 recovery promised but not quantified.

Debottlenecking capex and ₹240 Cr target execution uncertain

Medium

₹25 Cr capex deployed through 2027 must unlock ₹240 Cr/qtr run-rate. Q2 beat validates progress, but reaching ₹240 Cr requires sustained momentum and new product ramps.

Innovation timelines (DME March 2027, TNBC Q3) may not commercialize as expected

Medium

Trials are early-stage; timelines to clinical approval, manufacturing, and revenue uncertain. TNBC is out-licensed (not owned by Godavari).

FII selling and valuation drawdown eroding equity story

Medium

FII holders down 76 bps in one quarter; stock down 46% from ATH. Further multiple compression could trigger forced selling if loss persists.

What to watch next

Key catalysts and verdicts
  • 1 · H2 FY27 sugar seasonality and segment turnaround

    Management expects Q3/Q4 to be profitable seasonally. Watch for (a) actual sugar revenue and EBITDA in Q3 FY27 results, (b) whether monsoon recovery and improved feedstock availability narrow segment losses, and (c) whether multi-feedstock ethanol facility reduces drag.

  • 2 · ₹25 Cr capex deployment and new specialty chemical ramp

    Capex is supposed to unlock 20-25 new specialty chemicals and push bio-chemicals toward ₹240 Cr/qtr. Watch for (a) capex spend progress in FY27 H2, (b) new product launches materializing in April-Sept 2027 window, and (c) revenue contribution visible by Q3/Q4 FY27.

  • 3 · DME pilot and TNBC trial outcomes

    DME pilot results due March 2027; TNBC preliminary efficacy due Q3 FY27. Watch for (a) technical feasibility signals, (b) TNBC safety/efficacy data, and (c) out-licensing traction. Disappoint on both and near-term catalysts lose credibility.

The debate

Rating: Hold. For existing holders who believe in the chemicals thesis and can tolerate ongoing quarterly losses. For fresh entry, wait for either (a) a quantified consolidated profitability timeline with a date, or (b) two consecutive quarters of chemicals hitting ₹240+ Cr run-rate while sugar losses materially narrow to ₹5 Cr EBITDA or less. The ₹15.2 Cr consolidated loss is the number to track.

H2 FY27 consolidated net loss is the verdict: if it narrows to ₹10 Cr or less across Q3+Q4, the thesis holds. If it remains above ₹20 Cr, the sugar hedge failed and profitability is pushed to FY28 or later. Watch that number.

Informational and educational content only. Not investment advice.